tbuckley/cabot-search huggingface dataset:
Значення фекального кальпротектину при ротавірусній інфекції в дітей раннього віку
Authors: O.Ye. Abaturov, Yu.Yu. Stepanova
Journal: GASTROENTEROLOGY (2014)

У статті подані результати дослідження, що характеризують рівень кальпротектину в калі в дітей раннього віку з ротавірусною інфекцією. Метою даного дослідження було визначення значення флуктуацій концентрації фекального кальпротектину при ротавірусній інфекції в дітей. Обстежено 105 дітей раннього віку, у яких був діагностований ротавірусний гастроентерит. Показана динаміка зміни вмісту кальпротектину в калі в дітей із ротавірусною інфекцією. Встановлено відсутність залежності концентрації кальпротектину в калі від тяжкості перебігу ротавирусного ентериту. Показано обернено пропорційний зв’язок між наявністю дисахаридазної недостатності та рівнем кальпротектину в калі в гострий період ротавірусної інфекції в дітей.
Phylogeny of the CDKN2a/p14ARF locus.
Authors: Marc S. Greenblatt, Joan A. Murphy, Carole McBride, Kathleen P. Seiler, Jeffrey P. Bond
Journal: Cancer Research (2004)

3272  The CDKN2a locus on human chromosome 9 at 9p21 encodes two tumor suppressor proteins: CDKN2a protein (p16, Ink4a), a cell cycle inhibitor in the RB pathway, and p14ARF (ARF), which is linked to both the p53 and RB pathways. This locus is of considerable evolutionary interest for several reasons. Adjacent to CDKN2a is CDKN2b; these proteins are likely the result of a duplication event from an ancestral gene, although only CDKN2a appears to be important in carcinogenesis. The CDKN2a (p16) and ARF proteins share exon 2 in different reading frames, but have distinct first exons. It appears that ARF exon 1β was inserted into this locus, but it is uncertain when in evolutionary history this occurred. It also has been suggested that a gene conversion event has occurred in exon 2 of the human gene. We have updated the CDKN2a phylogenetic tree based on published sequences and data from ongoing genome projects, and we performed computational studies of intragenic evolution. Our data suggest that no gene conversion event has occurred in CDKN2a evolutionary history. We cannot determine whether exon 1β inserted into the region before or after the CDKN2a/b duplication. Additionally, the amount of evolutionary variation among the existing set of p16 sequences is lower than a similar set of p53 sequences. The observed evolutionary variation is not sufficient to state with statistical significance whether a given amino acid within p16 is “absolutely conserved”. Further phylogenetic comparisons of CDKN2a cDNA and genomic DNA are ongoing to reconstruct the evolutionary history of this important growth control locus.
1259P Real-world next-generation sequencing (NGS) and treatment (Tx) patterns in non-small cell lung cancer (NSCLC) patients (pts) with MET exon 14 skipping mutations (METex14)
Authors: X. Le, J. Martinalbo, A. Holynskyj, W.C. Rhodes, W-H. Wu, J. Kim, V. Pretre, F. Ye, J. Morrissette
Journal: Annals of Oncology (2021)
929TiP HERODOTUS: Head and neck cancers international COVID-19 collaboration: An international registry on head and neck cancer with COVID-19
Authors: A. Psyrri, H. Mehanna, P. Economopoulou, S. Porceddu, J. Waldron, E.H. Wen Ong, M.L.K. Chua, N.F. Saba, N. Basté, S. Cavalieri, G. Fountzilas, L.F. Licitra
Journal: Annals of Oncology (2021)
Abstract 11376: Prognostic Value of the Combination of Simple Risk Index and Geriatric Nutritional Risk Index in Patients Admitted for Acute Decompensated Heart Failure With Reduced or Preserved LVEF
Authors: Takahisa Yamada, Takashi Morita, Yoshio Furukawa, Shunsuke Tamaki, Yusuke Iwasaki, Masato Kawasaki, Atsushi Kikuchi, Tsutomu Kawai, Masahiro Seo, Jun Nakamura, Makoto Abe, Kyoko Yamamoto, Kiyomi Kayama, Masatsugu Kawahira, Kazuya Tanabe, Masatake Fukunami
Journal: Circulation (2018)

Backgrounds: Increased heart rate (HR) and low systolic blood pressure (SBP) are associated with adverse clinical outcomes in patients admitted for acute decompensated heart failure (ADHF), and sim...
The origins of music in (musi)language
Authors: Evelina Leivada
Journal: Behavioral and Brain Sciences (2021)

Abstract The view of music as a byproduct of other cognitive functions has been deemed incomplete or incorrect. Revisiting the six lines of evidence that support this conclusion, it is argued that it is unclear how the hypothesis that music has its origins in (musi)language is discarded. Two additional promising research lines that can support or discard the byproduct hypothesis are presented.
Abstract P241: Correlates of Abdominal Aortic Diameters Among Persons without Abdominal Aortic Aneurysms: The Atherosclerosis Risk in Communities (ARIC) Study
Authors: Lu Yao, Aaron Folsom, Alvaro Alonso, James Pankow, Pamela Lutsey, Emil Missov, Frank Lederle, Christie Ballantyne, Weihong Tang
Journal: Circulation (2016)

Background: Evidence from cohort studies has demonstrated that advanced age, male gender, white race, greater height, smoking, hypertension and dyslipidemias for abdominal aortic aneurysm (AAA). However, the associations of these risk factors with increased abdominal aortic diameters among persons without AAA have not been extensively examined in prospective studies; such evidence may help further with AAA prevention strategies. Methods: We included participants of the ARIC cohort who underwent abdominal ultrasound in 2011-2013. We excluded participants with prior clinical AAAs identified from hospital discharge codes, death codes, Medicare outpatient claims, or an infrarenal abdominal aortic maximum diameter ≥ 3 cm in the ultrasound exam. Risk factors, when available, across five visits during 1987-2013 were analyzed as the weighted average, weighting by the number of years exposed, in logistic regression models to examine the relationships with risk of being in the highest quartile of infrarenal abdominal aortic maximum diameter (≥2.2 cm). The models were adjusted for attrition by using inverse probability weighting. Results: Of 5,671 participants included in the analysis, 40.4% were men and 22.1% were blacks. After adjustment for age, sex, race, and ARIC field center, greater smoking pack years and height were associated with great abdominal aortic diameter (odds ratio Highest Quintile vs. Lowest Quintile: 1.66 [95% CI: 1.41, 1.96; P for linear trend: 0.027] for smoking pack years, and 2.61 [95% CI: 1.99, 3.43; P for linear trend: &lt;0.001] for height), and high-density lipoprotein cholesterol was negatively associated with great abdominal aortic diameter (odds ratio Highest Quintile vs. Lowest Quintile: 0.69 [95% CI: 0.55, 0.87; P for linear trend: 0.007]). Men were more likely (odds ratio: 4.15 [95% CI: 3.67, 4.69]; P &lt;0.001) to be in the highest quartile of abdominal aortic diameters than women; and the association persisted after further adjusting for height and smoking pack years (odds ratio: 2.34 [95% CI: 1.94, 2.84]; P &lt;0.001). Other established AAA risk factors were not associated with abdominal aortic diameter. Conclusions: Among well-established AAA risk factors, male gender, cigarette smoking and greater height were positively associated while high-density lipoprotein cholesterol was inversely associated with greater abdominal aortic diameters among persons without AAA in this large population-based cohort.
879P Adaptive radiotherapy in head and neck cancer: A prospective dosimetric and volumetric study
Authors: A. Pandey, R.K. Seam, L. Pandey, D. Malik, R. Mahajan, B. Srinivasavittal Rao Sumithra, P. Inampudi, M. Acharya, S. Chaparala, F.D. Patel
Journal: Annals of Oncology (2021)
199TiP Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA
Authors: F. Marmé, C. Hanusch, J. Furlanetto, C. Denkert, T. Link, M. Untch, J-U. Blohmer, C. Jackisch, M. Reinisch, K.E. Rhiem, A. Schneeweiss, C. Solbach, L. Schöllhorn, P.A. Fasching, J. Rey, S. Loibl
Journal: Annals of Oncology (2021)
Rates of Prenatal Cannabis Use Among Pregnant Women Before and During the COVID-19 Pandemic
Authors: Kelly C. Young-Wolff, G. Thomas Ray, Stacey E. Alexeeff, Sara R. Adams, Monique B. Does, Deborah Ansley, Lyndsay A. Avalos
Journal: JAMA (2021)

Nora D. Volkow, MD; Beth Han, MD, PhD, MPH; Wilson M. Compton, MD, MPE; Elinore F. McCance-Katz, MD, PhD
LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO
Authors: C. Cremolini, D. Rossini, C. Antoniotti, F. Pietrantonio, S. Lonardi, L. Salvatore, F. Marmorino, B. Borelli, M. Ambrosini, G. Barsotti, B. Di Stefano, G. Masi, A. Boccaccino, S. Tamberi, E. Tamburini, L.G. Frassineti, F. Simionato, G. Fontanini, L. Boni, A. Falcone
Journal: Annals of Oncology (2021)
1806P Analysis of germ-line mutations in non-syndromic malignancies with concurrent pathogenic variants in BRCA1, BRCA2, PALB2, ATM, CHEK2, and RAD51C/D
Authors: E.M. Miller, J. Mullins, A. Jain, A. Chaudhry, D. Mi, R. Usman, T. Jones, Y. Baca, J. Xiu, W.M. Korn, S. Cummings, G. Vidal
Journal: Annals of Oncology (2021)
509TiP REPROGRAM-01, a phase II study of regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer
Authors: E. Klajer, M. Jary, C. Borg, S. Kim, D. Vernerey, J. Henriques, T. N'Guyen, M. Nasri, H. Almotlak, J. Babre, A. Meurisse, S. Fratte, F. Fein, F. Calcagno, L. Chanut, L. Spehner, M. Rebucci-Peixoto, A. Vienot
Journal: Annals of Oncology (2021)
886P Circulating tumor DNA kinetics in recurrent/metastatic head &amp; neck squamous cell cancer (R/M HNSCC) patients
Authors: K. Taylor, J. Zou, J. Burgener, E. Zhao, D. Torti, M. Oliva, A. Spreafico, A.R. Hansen, R. Jang, S.S. McDade, V.M. Coyle, M. Lawler, E. Elimova, S.V. Bratman, L.L. Siu
Journal: Annals of Oncology (2021)
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Authors: Michael Hallek, Othman Al‐Sawaf
Journal: American Journal of Hematology (2021)

Abstract Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia. It typically occurs in elderly patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that interfere with the regulation of proliferation and of apoptosis in clonal B‐cells. Diagnosis The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B‐lymphocytes, which identify a clonal B‐cell population carrying the CD5 antigen as well as typical B‐cell markers. Prognosis and staging The clinical staging systems provide prognostic information by using the results of physical examination and blood counts. Various biological and genetic markers provide additional prognostic information. Deletions of the short arm of chromosome 17 ( del[17p] ) and/or mutations of the TP53 gene predict resistance to chemoimmunotherapy and a shorter time to progression with most targeted therapies. The CLL international prognostic index integrates genetic, biological, and clinical variables to identify distinct risk groups of patients with CLL. Therapy Only patients with active or symptomatic disease or with advanced Binet or Rai stages require therapy. When treatment is indicated, several therapeutic options exist: a combination of the B‐cell lymphoma 2 (BCL2) inhibitor venetoclax with obinutuzumab, monotherapy with inhibitors of Bruton tyrosine kinase (BTK) such as ibrutinib and acalabrutinib, or chemoimmunotherapy. At relapse, the initial treatment may be repeated, if the treatment‐free interval exceeds 3 years. If the disease relapses earlier, therapy should be changed using an alternative regimen. Patients with a del(17p) or TP53 mutation are usually resistant to chemotherapy and should, therefore, be treated with targeted agents. Future challenges Combinations of targeted agents are now being investigated to create efficient, potentially curative therapies of CLL with fixed duration. One of the most relevant questions currently addressed in clinical trials is the comparison of monotherapies with BTK inhibitors with fixed duration combination therapies. Moreover, the optimal sequencing of targeted therapies remains to be determined. Alternative therapies are needed for patients with BTK and BCL2 inhibitor double‐refractory disease.
LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study
Authors: E.B. Garon, M.L. Johnson, A.E. Lisberg, A. Spira, N. Yamamoto, R.S. Heist, J.M. Sands, K. Yoh, F. Meric-Bernstam, S. Kitazono, J. Greenberg, F. Kobayashi, Y. Kawasaki, L. Jukofsky, K. Nakamura, T. Shimizu
Journal: Annals of Oncology (2021)
1827P European Society for Medical Oncology (ESMO)/International Society of Geriatric Oncology (SIOG) Joint Working Group (WG) survey on management of older patients with cancer
Authors: C. Baldini, E.G.C. Brain, S. Rostoft, L. Biganzoli, V. Goede, R. Kanesvaran, E. Quoix, C. Steer, D. Papamichael, H. Wildiers
Journal: Annals of Oncology (2021)
1217P EGFR TKIs in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG)
Authors: S. Miura, T-C. Hsia, J-Y. Hung, H.A. Jung, J-Y. Shih, C-K. Park, S.H. Lee, T. Okamoto, H.K. Ahn, Y.C. Lee, Y. Sato, S.S. Lee, C. Mascaux, H. Daoud, A. Märten, S. Popat
Journal: Annals of Oncology (2021)
219P Accuracy of MRI to assess response after neoadjuvant chemotherapy according to immunohistochemical breast cancer subtypes: A systematic review and meta-analysis
Authors: L.M. Janssen, B.M. den Dekker, K.G.A. Gilhuijs, P.J. van Diest, E. van der Wall, S.G. Elias
Journal: Annals of Oncology (2021)
Jejunostomy tube removed after pancreaticoduodenectomy using single-balloon endoscopy
Authors: Keiichi Haga, Tomoyoshi Shibuya, Kei Nomura, Mayuko Haraikawa, Osamu Nomura, Akihito Nagahara
Journal: Endoscopy (2021)

A 70-year-old woman underwent a subtotal stomach-preserving pancreaticoduodenectomy with a modified Child’s reconstruction method for an intraductal papillary mucinous neoplasm. A jejunostomy feeding tube was temporarily placed ([Fig. 1]) but could not be removed 1 month after the operation. No abnormalities were found on X-ray ([Fig. 2]). Enteroscopy was deemed necessary to investigate why the tube could not be removed.
Non-A, Non-B Hepatitis
Authors: Stephen M. Feinstone
Journal: JAMA (1978)

Sensitive serologic tests capable of diagnosing essentially all infections with hepatitis A virus and hepatitis B virus (HBV) have shown that certain patients with a viral hepatitis-like syndrome have neither hepatitis A nor hepatitis B. Such cases of non-A, non-B hepatitis have been most frequently recognized in studies of transfusion-associated hepatitis. Less than 20% of posttransfusion hepatitis is due to HBV if only blood from voluntary donors that has been screened by thirdgeneration tests for the presence of hepatitis B surface antigen is used for transfusion. Type A hepatitis rarely, if ever, results from blood transfusion.<sup>1,2</sup>Thus, most transfusion-associated hepatitis in the United States has an unknown cause. Non-A, non-B hepatitis resembles type B disease in several respects. First, the common route of infection by blood or blood products indicates that a chronic carrier state must exist in relatively asymptomatic persons. Second, non-A, non-B hepatitis has been found to
Twenty Years of Radiation Therapy of Unresectable Intrahepatic Cholangiocarinoma: Internal or External? A Systematic Review and Meta-Analysis
Authors: Qian Yu, Chenyu Liu, Anjana Pillai, Osman Ahmed
Journal: Liver Cancer (2021)

Both external beam radiation therapy (EBRT) and selective-internal radiation therapy (SIRT) are implemented to treat unresectable intrahepatic cholangiocarcinoma (iCCA). The present study aimed to evaluate the efficacy of EBRT and SIRT in managing iCCA through a systematic review and meta-analysis.PubMed and Cochrane database were queried to search for studies published from January 2000 toJune 2020 without language restrictions. Median survival time, overall survival, and radiological response were extracted. Secondary outcomes such as complication rates, predictors of survival, and downstage to surgery were pooled. Patient-level survival data were obtained to generate Kaplan-Meier survival graph. Pooled outcomes were analyzed with a random-effect model.Twenty-nine and 20 studies including 732 and 443 patients from the SIRT and EBRT groups were included in the present study. From initial radiation treatment, the median survival time for patients who underwent SIRT and EBRT were 12.0 (95% confidence interval [CI]: 10.8-14.6) and 13.6 (95% CI: 11.1-16.0) months, respectively. As first-line therapy, the median survival time was 36.1 (95% CI: 20.6-39.5) months for SIRT and 11.0 (95% CI: 9.3-13.6) months for EBRT. Both radiation modalities were effective in downstaging initially unresectable iCCA to surgery (SIRT: 30.5%; EBRT: 18.3%). Patients in the SIRT group encountered more post-embolization abdominal pain (6.9 vs. 2.2%), ulcer (1.0 vs. 0.5%), nausea (1.6 vs. 0.7%), anorexia (5.9 vs. 0%), thrombocytopenia (7.3 vs. 6.0%), hyperbilirubinemia (5.2 vs. 2.1%), and hypoalbuminemia (13.2 vs. 3.3%), whereas EBRT was associated with higher rates of anemia (0.6 vs. 7.5%) and neutropenia (6.5 vs. 11.0%).Both EBRT and SIRT were safe and effective in treating unresectable iCCA. However, available evidence was highly heterogeneous regarding patient population, limiting fair comparison between 2 radiation modalities. Future high-quality comparative studies are warranted.
Pain Management Video Reduces Opioid Use After Cesarean Delivery
Authors: Anita Slomski
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 13432: Pulmonary Artery Pressure-Guided Therapy in Patients With Heart Failure Using the CardioMEMS Device and HF Readmissions: Analysis of the National Readmissions Database
Authors: Ernesto A Ruiz, Aaqib Malik, Kampaktsis Polydoros, Alexandros Briasoulis
Journal: Circulation (2021)

Introduction: Pulmonary artery pressure (PAP)-guided therapy in patients with heart failure (HF) using the CardioMEMS device (CMM), an implantable PAP sensor, has shown to reduce hospitalizations in prior studies. Hypothesis: We sought to evaluate the clinical benefit of the CMM device in regard to readmission rates using the National Readmission Database (NRD). Methods: We queried the NRD to identify patients who underwent CMM implantation (CPT code 33289) between years 2014 to 2018 and studied their HF readmissions. We compared CMM patients and their readmissions with a matched cohort of patients with HF without CMM. Multivariate Cox regression analysis was performed to adjust for other predictors of readmissions. Results: Prior to matching we identified 3,965,188 weighted HF patients without CMM and 1528 patients with CMM. After propensity score matching for several patient and hospital related characteristics, the cohort consisted of 1528 patients with CMM and 1528 with HF without CMM. Before matching CMM patients were younger, more frequently males, with higher rates of prior myocardial infarction and chronic kidney disease. Readmission rates at 30-days were 17.6% vs. 21% for patients with vs. without CMM respectively and remained statistically significant after matching (17.5% vs. 22.7%, p=0.01). The rates of 90-day (29.1% vs 36.5%, p=0.002) and 180-day (40.1% vs. 46.6%, p=0.03) readmissions were lower in the CMM group (Figure). In multivariable regression models, CMM was associated with lower risk of readmissions (HR, 0.78, 95% CI 0.64-0.94, p=0.01). Conclusions: The CardioMEMS device was associated with reduced HF rehospitalization rates in a nationally representative cohort of HF patients
Occupational dermatoses during the second wave of the COVID‐19 pandemic: a UK prospective study of 805 healthcare workers
Authors: J.M. Gao, R. Goiriz, S. Rajpopat, P. Goldsmith
Journal: British Journal of Dermatology (2021)

Journal Article Occupational dermatoses during the second wave of the COVID‐19 pandemic: a UK prospective study of 805 healthcare workers Get access J.M. Gao, J.M. Gao Department of Dermatology Barts Health NHS Trust London UK https://orcid.org/0000-0002-5105-5920 Search for other works by this author on: Oxford Academic Google Scholar R. Goiriz, R. Goiriz Department of Dermatology Barts Health NHS Trust London UK Search for other works by this author on: Oxford Academic Google Scholar S. Rajpopat, S. Rajpopat Department of Dermatology Barts Health NHS Trust London UK Search for other works by this author on: Oxford Academic Google Scholar P. Goldsmith P. Goldsmith Department of Dermatology Barts Health NHS Trust London UK Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 186, Issue 2, 1 February 2022, Pages 374–376, https://doi.org/10.1111/bjd.20779 Published: 01 February 2022